Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia

(2011) N Konstandin et al.   LEUKEMIA

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

(2011) M J Walter et al.   LEUKEMIA

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

TET Genes: new players in DNA demethylation and important determinants for stemness

(2010) Fabian Mohr et al.   EXPERIMENTAL HEMATOLOGY

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

(2010) F. Thol et al.   HAEMATOLOGICA

Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)

(2010) A Pardanani et al.   LEUKEMIA

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

(2010) Myunggon Ko et al.   NATURE

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

(2010) Gorica Nikoloski et al.   NATURE GENETICS

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

(2009) A. M. Jankowska et al.   BLOOD

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

(2009) M. E. Figueroa et al.   BLOOD

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

(2009) A Tefferi et al.   LEUKEMIA

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Myelodysplastic Syndromes

(2009) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

(2009) M. Tahiliani et al.   SCIENCE

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Epigenetics: Modifications, Screening, and Therapy

(2007) Gal-Yam Einav Nili et al.   Annual Review of Medicine